Drug interactions between antineoplastic and antiretroviral therapies: Implications and management for clinical practice

Critical Reviews in Oncology/Hematology

Volumn 72, Issue 1, 2009, Pages 10-20

  Mounier, Nicolas ^a   Katlama, Christine ^b,c,d   Costagliola, Dominique ^b,c,d   Chichmanian, Rose Marie ^a   Spano, Jean Philippe ^d  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c INSERM   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

AIDS related malignancies; Antineoplastic agents; Antiretroviral drugs; Cytochrome P450; Drug interactions

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450; DACARBAZINE; DAUNORUBICIN; DELAVIRDINE; DIDANOSINE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; INDINAVIR; INDINAVIR PLUS RITONAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; PACLITAXEL; PREDNISONE; PROCARBAZINE; PROTEINASE INHIBITOR; RITONAVIR; RITUXIMAB; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TOPOTECAN; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VINDESINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADENOCARCINOMA; AIDS RELATED COMPLEX; ANEMIA; ANUS CANCER; AREA UNDER THE CURVE; AUTONOMIC NEUROPATHY; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CAUSE OF DEATH; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL TRIAL; CRYOTHERAPY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TRANSFORMATION; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOALBUMINEMIA; INFECTION; KAPOSI SARCOMA; LIVER DYSFUNCTION; LOW LEVEL LASER THERAPY; MALIGNANT NEOPLASTIC DISEASE; MITOCHONDRIAL DNA DEPLETION SYNDROME; MORTALITY; MUCOSA INFLAMMATION; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PERIPHERAL NEUROPATHY; REVIEW; SURVIVAL TIME; UTERINE CERVIX CANCER;

ANTINEOPLASTIC AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; NEOPLASMS;

EID: 69249224593     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2008.10.013     Document Type: Review

References (77)

1. Biggar R.J., Curtis R.E., Cote T.R., Rabkin C.S., and Melbye M. Risk of other cancers following Kaposi's sarcoma: relation to acquired immunodeficiency syndrome. Am J Epidemiol 139 (1994) 362-368
2. Goedert J.J., Cote T.R., Virgo P., et al. Spectrum of AIDS-associated malignant disorders. Lancet 351 (1998) 1833-1839
3. Engels E.A., Pfeiffer R.M., Goedert J.J., et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 20 (2006) 1645-1654
4. Bonnet F., Lewden C., May T., et al. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. Cancer 101 (2004) 317-324
5. Clifford G.M., Polesel J., Rickenbach M., et al. Cancer risk in the Swiss HIV cohort study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 97 (2005) 425-432
6. Herida M., Mary-Krause M., Kaphan R., et al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 21 (2003) 3447-3453
7. Costagliola D. Cancer risk and mortality for patients with HIV in the combination antiretroviral therapy era: evolving epidemiology. J Clin Oncol Suppl. (2007) 462-466
8. Pantanowitz L., Schlecht H.P., and Dezube B.J. The growing problem of non-AIDS-defining malignancies in HIV. Curr Opin Oncol 18 (2006) 469-478
9. Bruyand M., Thiebaut R., Lawson-Ayayi S., and Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA). Immunodeficiency and risk of AIDS-defining and non-AIDS-defining cancers: ANRS CO3 Aquitaine Cohort, 1998 to 2006. Conference on retroviruses and opportunistic infections. Boston, February 3-6 (2008) [Abstract 15]
10. Biggar R.J., Engels E.A., Ly S., et al. Survival after cancer diagnosis in persons with AIDS. J Acquir Immune Defic Syndr 39 (2005) 293-299
11. Di Lorenzo G., Konstantinopoulos P.A., Pantanowitz L., Di Trolio R., De Placido S., and Dezube B.J. Management of AIDS-related Kaposi's sarcoma. Lancet Oncol 8 (2007) 167-176
12. Mounier N., Spina M., and Gisselbrecht C. Modern management of non-Hodgkin lymphoma in HIV-infected patients. Br J Haematol 136 (2007) 685-698
13. Barry M., Mulcahy F., Merry C., Gibbons S., and Back D. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet 36 (1999) 289-304
14. Sekine I., and Saijo N. Polymorphisms of metabolizing enzymes and transporter proteins involved in the clearance of anticancer agents. Ann Oncol 12 (2001) 1515-1525
15. Northfelt D.W., Dezube B.J., Thommes J.A., et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 16 (1998) 2445-2451
16. Stewart S., Jablonowski H., Goebel F.D., et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol 16 (1998) 683-691
17. Gill P.S., Wernz J., Scadden D.T., et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 14 (1996) 2353-2364
18. Gill P.S., Tulpule A., Espina B.M., et al. Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma. J Clin Oncol 17 (1999) 1876-1888
19. Welles L., Saville M.W., Lietzau J., et al. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma. J Clin Oncol 16 (1998) 1112-1121
20. Vaccher E., Spina M., and di Gennaro G. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related non-Hodgkin lymphoma. Cancer 91 (2001) 155-163
21. Little R.F., Pittaluga S., Grant N., et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with doseadjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 101 (2003) 4653-4659
22. Boue F., Gabarre J., Gisselbrecht C., et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol 24 (2006) 4123-4128
23. Kaplan L.D., Lee J.Y., Ambinder R.F., et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS Malignancies Consortium Trial 010. Blood 106 (2005) 1538-1543
24. Hartmann P., Rehwald U., Salzberger B., et al. BEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection. Ann Oncol 14 (2003) 1562-1569
25. DHHS Adults and Adolescents Antiretroviral Treatment Guidelines Panel's - US Guideline 2008. New York State Department of Health AIDS Institute. Clinical Guidelines. HIV Drug-Drug Interactions. Available at: http://www.hivguidelines.org. Accessed July 10, 2003.
26. Faragon J.J., and Piliero P.J. Drug interactions associated with HAART: focus on treatments for addiction and recreational drugs. AIDS Read 13 (2003) 433-450
27. Scripture C.D., and Figg W.D. Drug interactions in cancer therapy. Nat Rev Cancer 6 (2006) 546-558
28. Antoniou T., and Tseng A.L. Interactions between antiretrovirals and antineoplastic drug therapy. Clin Pharmacokinet 44 (2005) 111-145
29. Cresteil T., Monsarrat B., Alvinerie P., Tréluyer J.M., Vieira I., and Wright M. Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res 54 (1994) 386-392
30. Venook A.P., Egorin M.J., Rosner G.L., et al. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol 16 (1998) 1811-1819
31. Brown T., Havlin K., Weiss G., et al. A phase I trial of taxol given by a 6-hour intravenous infusion. J Clin Oncol 9 (1991) 1261-1267
32. Seidman A.D., Hochhauser D., Gollub M., et al. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol 14 (1996) 1877-1884
33. Panday N.V.R., Hoetelmans R.M., van Heeswijk R.P., et al. Paclitaxel in the treatment of human immunodeficiency virus 1-associated Kaposi's sarcoma-drug-drug interactions with protease inhibitors and a nonnucleoside reverse transcriptase inhibitor: a case report study. Cancer Chemother Pharmacol 43 (1999) 516-519
34. Duchin K., Sun J., Tan M., et al. Pharmacokinetics of low-dose paxene (paclitaxel) in patients with refractory or relapsed AIDS-related Kaposi's sarcoma. Proc Am Soc Clin Oncol (1997) A829 [Abstract]
35. Schwartz J.D., Howard W., and Scadden D.T. Potential interaction of antiretroviral therapy with paclitaxel in patients with AIDS-related Kaposi's sarcoma. AIDS 13 (1999) 283-284
36. Bundow D., and Aboulafia D.M. Potential drug interaction with paclitaxel and highly active antiretroviral therapy in two patients with AIDS-associated Kaposi sarcoma. Am J Clin Oncol 27 (2004) 81-84
37. Parameswaran R., Sweeney C., and Einhorn L.H. Interaction between highly active antiretroviral therapy (HAART) and taxanes: a report of two cases. Proc Am Soc Clin Oncol 21 (2002) A2194
38. Tran A., Jullien V., Alexandre J., et al. Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther 79 (2006) 570-580
39. Hudis C.A., Seidman A.D., Crown J.P., et al. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 14 (1996) 58-65
40. Alexandre J., Bleuzen P., Bonneterre J., et al. Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients. J Clin Oncol 18 (2000) 562-573
41. Alexandre J., Rey E., Girre V., et al. Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study. Ann Oncol 18 (2007) 168-172
42. Bardelmeijer H.A., Ouwehand M., Buckle T., et al. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res 62 (2002) 6158-6164
43. Huang Z., Roy P., and Waxman D.J. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem Pharmacol 59 (2000) 961-972
44. Freyer G., Tranchand B., Ligneau B., et al. Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study. Br J Clin Pharmacol 50 (2000) 315-324
45. Ratner L., Lee J., Tang S., et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 19 (2001) 2171-2178
46. Bower M., Powles T., Stebbing J., and Thirlwell C. Potential antiretroviral drug interactions with cyclophosphamide, doxorubicin, and etoposide. J Clin Oncol 23 (2005) 1328-1329
47. Bower M., McCall-Peat N., Ryan N., et al. Protease inhibitors potentiate chemotherapy-induced neutropenia. Blood 104 (2004) 2943-2946
48. Yao D., Ding S., Burchell B., Wolf C.R., and Friedberg T. Detoxication of vinca alkaloids by human P450 CYP3A4-mediated metabolism: implications for the development of drug resistance. J Pharmacol Exp Ther 294 (2000) 387-395
49. Makinson A., Martelli N., Peyrière H., Turriere C., Le Moing V., and Reynes J. Profound neutropenia resulting from interaction between antiretroviral therapy and vinblastine in a patient with HIV-associated Hodgkin's disease. Eur J Haematol 78 (2007) 358-360
50. Kotb R., Vincent I., Dulioust A., et al. Life-threatening interaction between antiretroviral therapy and vinblastine in HIV-associated multicentric Castleman's disease. Eur J Haematol 76 (2006) 269-271
51. Smith N.F., Figg W.D., and Sparreboom A. Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol In Vitro 20 (2006) 163-175
52. Mathijssen R.H., van Alphen R.J., Verweij J., et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 7 (2001) 2182-2194
53. Corona G., Vaccher E., Sandron S., et al. Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma. Clin Pharmacol Ther 83 (2008) 601-606
54. Zhang D., Chando T.J., Everett D.W., Patten C.J., Dehal S.S., and Humphreys W.G. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos 33 (2005) 1729-1739
55. Corona G., Vaccher E., Cattarossi G., Sartor I., and Toffoli G. Potential hazard of pharmacokinetic interactions between lopinavir-ritonavir protease inhibitors and irinotecan. AIDS 19 (2005) 2043-2044
56. Garcia-Carbonero R., and Supko J.G. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 8 (2002) 641-661
57. Sparano J.A., Wiernik P.H., Hu X., Sarta C., Henry D.H., and Ratech H. Saquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma. Med Oncol 15 (1998) 50-57
58. Sparano J.A., Lee S., Chen M.G., et al. Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494). J Clin Oncol 22 (2004) 1491-1500
59. Goeptar A.R., Te Koppele J.M., Lamme E.K., Piqué J.M., and Vermeulen N.P. Cytochrome P450 2B1-mediated one-electron reduction of adriamycin: a study with rat liver microsomes and purified enzymes. Mol Pharmacol 44 (1993) 1267-1277
60. Toffoli G., Corona G., Cattarossi G., et al. Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma. Ann Oncol 15 (2004) 1805-1809
61. Fumagalli L., Zucchetti M., Parisi I., et al. The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma. Cancer Chemother Pharmacol 45 (2000) 495-501
62. Rotea W., and Saad E.D. Targeted drugs in oncology: new names, new mechanisms, new paradigm. Am J Health Syst Pharm 60 (2003) 1233-1245
63. Li J., Karlsson M.O., Brahmer J., et al. CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. J Natl Cancer Inst 98 (2006) 1714-1723
64. Li J., Zhao M., He P., Hidalgo M., and Baker S.D. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res 13 (2007) 3731-3737
65. Delbaldo C. Pharmacokinetic-pharmacodynamics relationships of imatinib (Glivec). Therapie 62 (2007) 87-90
66. Faivre S., Delbaldo C., Vera K., et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24 (2006) 25-35
67. Gutmann H., Fricker G., Drewe J., Toeroek M., and Miller D.S. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol Pharmacol 56 (1999) 383-389
68. Deng L., Tatebe S., Lin-Lee Y.C., Ishikawa T., and Kuo M.T. MDR and MRP gene families as cellular determinant factors for resistance to clinical anticancer agents. Cancer Treat Res 112 (2002) 49-66
69. Lucia M.B., Rutella S., Leone G., Larocca L.M., Vella S., and Cauda R. In vitro and in vivo modulation of MDR1/p-glycoprotein in HIV-infected patients administered highly active antiretroviral therapy and liposomal doxorubicin. J Acquir Immune Defic Syndr Hum Retrovirol 30 (2002) 369-378
70. Walker R.E., Parker R.I., Kovacs J.A., et al. Anemia and erythropoiesis in patients with the acquired immunodeficiency syndrome and Kaposi sarcoma with zidovudine. Ann Intern Med 108 (1988) 372-376
71. Moyle G.J., and Sadler M. Peripheral neuropathy with nucleoside antiretroviral: risk factors, incidence and management. Drug Safe 19 (1998) 481-494
72. Mallal S.A., John M., Moore C.B., James I.R., and McKinnon E.J. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 14 (2000) 1309-1316
73. Mounier N., Vignot S., and Spano J.P. Update on clinical activity of CCI779 (temsirolimus), mTOR inhibitor. Bull Cancer 93 (2006) 1139-1143
74. Robertson M.J., Kahl B.S., Vose J.M., et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 25 (2007) 1741-1746
75. DAD Study Group, Friis-Moller N., Reiss P., et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 356 (2007) 1723-1735
76. Spano J.P., Atlan D., Breau J.L., and Farge D. AIDS and non-AIDS-related malignancies: a new vexing challenge in HIV-positive patients. Part I. Kaposi's sarcoma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma. Eur J Intern Med 13 (2002) 170-179
77. Spano J.P., Atlan D., Breau J.L., and Farge D. AIDS and non-AIDS-related malignancies: a new vexing challenge in HIV-positive patients. Part II. Cervical and anal squamous epithelial lesions, lung cancer, testicular germ cell cancers, and skin cancers. Eur J Intern Med 13 (2002) 227-232